GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » 5-Year Yield-on-Cost %

Processa Pharmaceuticals (Processa Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals 5-Year Yield-on-Cost %?

Processa Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Processa Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



PCSA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.62
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Processa Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Processa Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



Processa Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Processa Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Processa Pharmaceuticals  (NAS:PCSA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Processa Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals (Processa Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
Executives
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076

Processa Pharmaceuticals (Processa Pharmaceuticals) Headlines

From GuruFocus

Next Generation Chemotherapy: Improved Treatment for More Patients

By sperokesalga sperokesalga 06-14-2023